... Vascular endothelial growth factor inhibitors (VEGFi) Venous thromboembolism Pericardial disease Proteasome inhibitors QTc prolongation Radiotherapy Strain All experts involved in the development of these Guidelines have submitted declarations of interest. These have been compiled in a report...

... inhibitors surveillance protocol 38 Figure 16 Multiple myeloma drug-related cardiovascular toxicities 40 Figure 17 Cardiovascular monitoring in patients with multiple myeloma receiving proteasome inhibitors 41 Figure 18 Risk factors for venous thromboembolic events in patients with multiple myeloma...

... myeloma Muscle toxicity Proteasome inhibitors Multiple myeloma (MM) is a malignant plasma cell disorder, characterized by bone marrow infiltration, production of a monoclonal protein, and induction of osteolysis ( 1 , 2 ). The natural history of MM has profoundly changed with the introduction of novel...

..., Italy). The drug was reconstituted in water at a stock concentration of 2.6 mM and diluted in the cell culture medium before use. Proteasome inhibitor Z‐(Leu‐Leu‐Leu‐B(OH)2) (MG 262) and caspase‐3 inhibitor Ac‐Asp‐Glu‐Val‐Asp‐CHO (Ac‐DEVD‐CHO) were purchased from Enzo Life Sciences (Florence, Italy...

... renal rejection glomerular diseases progression of renal diseases proteasome inhibitors renal transplantation A dysregulation of the ubiquitin–proteasome (PS) pathway has been implicated in the pathogenesis of inherited and acquired diseases, including multiple sclerosis, amyotropic lateral...

.... It will be shown that p65/p50 heterodimer NF‐κB is activated by TNF‐α with concomitant degradation of both IκB‐α and IκB‐β. Furthermore, the use of proteasome inhibitors will show that TNF‐α‐dependent induction of MMP‐1, MMP‐3, ICAM‐1, and COX‐2 genes is regulated by NF‐κB. Nuclear extracts (10 μg of protein...

... in melanoma. Objectives To assess the effect of four structurally different proteasome inhibitors on human cutaneous melanoma‐derived cell lines. Methods Sixteen human cutaneous melanoma‐derived cell lines which are original were obtained from patients who were treated by two of the authors. Cells...

... quality control system ( Moore and Spiro (1994) J. Biol. Chem., 269, 12715–12721), we evaluated the effect which proteasome inhibitors have on the appearance of these free saccharide components. Employing as a model system castanospermine-treated BW5147 mouse T-lymphoma cells in which...

..., and neuroprotective effects of HDAC inhibitors are considered. SYSTEMIC TREATMENT PSYCHIATRIC CONSEQUENCES OF CANCER TREATMENT PSYCHIATRIC ADVERSE EFFECTS OF MTAs TYROSINE KINASE INHIBITORS MOLECULARLY TARGETED AGENTS PI3K/AKT INHIBITORS PARP INHIBITORS PROTEASOME INHIBITORS HDAC INHIBITORS Hair loss...

... reverse transcriptase inhibitors (NRTI’s) hepatitis C organophosphates arsenic thallium heavy metals tetrodotoxin ciguatera thalidomide saxitoxins ethanol disulfiram pyridoxine proteasome inhibitors Lyme disease leprosy rabies polio diptheria Human immunodeficiency virus HIV Infection...